Minerva Neurosciences, Inc (NERV) is a publicly traded Healthcare sector company. As of May 21, 2026, NERV trades at $5.30 with a market cap of $220.83M and a P/E ratio of -0.14. NERV moved +15.71% today. Year to date, NERV is +21.20%; over the trailing twelve months it is +264.49%. Its 52-week range spans $1.15 to $12.46. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces NERV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Minerva Appoints Jim O’Connor as CBO Ahead of Phase 3 Rolupe-ridone Trial: Minerva Neurosciences appointed Jim O’Connor as Chief Business Officer and General Counsel effective April 21, 2026, replacing departing President Geoff Race who will remain as consultant. O’Connor brings 20 years of legal and business experience, including negotiating over $130 million in financings, as Minerva readies its roluperidone Phase 3 trial.
| Metric | Value |
|---|---|
| Price | $5.30 |
| Market Cap | $220.83M |
| P/E Ratio | -0.14 |
| EPS | $-34.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.46 |
| 52-Week Low | $1.15 |
| Volume | 240 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-293.42M |
| Gross Margin | 0.00% |
2 analysts cover NERV: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.